Drug Guidance for Subsidy 02/01/2024 Tafamidis for treating transthyretin amyloid cardiomyopathy NRThe Ministry of Health’s Drug Advisory Committee has not recommended tafamidis for inclusion on th... See all × 02/01/2024 Tafamidis for treating transthyretin amyloid cardiomyopathy NRThe Ministry of Health’s Drug Advisory Committee has not recommended tafamidis for inclusion on the MOH List of Subsidised Drugs for treating wild-type or hereditary transthyretin amyloid cardiomyopathy. The decision was based on the unfavourable cost-effectiveness of tafamidis at the price proposed by the company, compared with standard management.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Capsule 61 mg National Heart Centre
ORAL Select a brand starting with the letter: V VYNDAMAX SOFT GELATIN CAPSULE 61MG [SIN15894P] VYNDAQEL SOFT GELATIN CAPSULE 20MG [SIN15893P]